Magidson, Sophie
Dana-Farber Cancer Institute
2 papers on CoChatORCID 0009-0007-4225-135X
Most cited papers
- Verified
Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma
Nadeem, O., Magidson, S., Midha, S., O'Donnell, E. K., Hartley-Brown, M. A., Sperling, A. S., Redd, R. A., Marto, M., Davie, C., Ricciardi, C., et al. (2023) · Blood
Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research
Cited by 37
- Verified
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
Nadeem, O., Aranha, M. P., Redd, R., Timonian, M., Magidson, S., Lightbody, E. D., Alberge, J.-B., Bertamini, L., Dutta, A. K., El-Khoury, H., et al. (2025) · Nature Communications
Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research
Cited by 20
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free